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Endothelin-1 (ET-l) was found to be a very potent stimulus for contraction and glycogenolysis n the perfused rat liver. At 1 nM it caused a dramatic 
increase in portal pressure of 22.1 f 2.7 cm water and enhanced the glucose output up to 3-fold. Extracellular Ca” and protein kinase C were 
involved in the signal transduction of ET-l. ET-l action does not seem to be mediated by endogenous eicosanoids. The effects of ET-l were 
significantly reduced in the presence of 1 PM Iloprost, a prostaglandin I, analogue, or by 100pM sin-l, a nitric oxide donor. In cultured hepatocytes, 
glycogenolysis was also stimulated by ET-l although to an extent too small to explain the high glucose output found in the perfused liver. 
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1. INTRODUCTION 
Endothelin-1 (ET-l) is a very potent vasoconstrictive 
peptide consisting of 21 amino acids. It was originally 
identified in the supernatants of porcine aortic endothe- 
lial cells [l]. After the cloning of cDNA for ET-l, two 
other isoforms, ET-2 and ET-3, have been found [2]. 
While ET-l is mainly synthesized by endothelial cells, 
the site of synthesis of the other isoforms is still uncer- 
tain [3]. The mechanisms underlying the vasoconstric- 
tive effect of ET-l on smooth muscle cells have been 
reported to be due to a mobilization of intracellular 
Ca” following phospholipase C activation by inositol 
Tris-phosphate [4,5] as well as to an influx of extracellu- 
lar Ca2’ through a calcium ion channel [6]. Protein ki- 
nase C was also reported to be involved in this process 
[5,7,8]. 
perisinusoidal stellate (fat-storing) cells that envelope 
the liver sinusoids [16] and are supposed to regulate the 
blood flow in the liver sinusoids [17] can contract after 
ET-l administration (Kawada et al., submitted). How- 
ever, it remains to be seen whether all the effects ob- 
served with ET-l in different liver cell systems can be 
reproduced in the whole organ. 
In the present study, we examined the effect of ET-l 
on portal pressure and glycogenolysis in the perfused 
rat liver. Under constant flow rate, portal pressure is 
dependent on the diameter of vessels and sinusoids; 
therefore, it is used as a parameter to detect their con- 
traction. Furthermore, the mechanism underlying the 
change of portal pressure and glycogenolysis induced 
by ET-l in the liver as well as the regulation of ET-l 
action by local mediators (eicosanoids and nitric oxide) 
was investigated. 
In the liver, ET-l is synthesized by sinusoidal endo- 
thelial cells [9]. Binding sites for [12’ IlET- in the liver 
have been found in rat liver plasma membranes [lo] and 
in fat-storing cells [11,12]. ET-l induces Ca2+ release 
and stimulation of glycogen phosphorylase in isolated 
hepatocytes [lo]. In primary cultures of hepatocytes it 
activates phospholipase C resulting in the generation of 
inositol phosphates [13]. ET-3 has been reported to in- 
duce the increase of portal vein pressure and glyco- 
genolysis in the perfused rat liver [14] and to stimulate 
Kupffer cells to produce prostaglandin (PC) Ez and 
inositol phosphates [15]. Recently we have shown that 
2. MATERIALS AND METHODS 
2.1. Materials 
Endothelin-1 (ET-l) was purchased from Sigma (Deisenhofen, Ger- 
many). Sin-l (3-morpholino-sydnonimine-N-ethylcarbamide) was a 
gift from Cassella AG (Frankfurt/Main, Germany). Sin-l was dis- 
solved just before use and was protected from light during the exper- 
iment. Collagenase type II (CLS II), fetal-calf serum and newborn-calf 
serum used for the preparation of hepatocyte cultures were from 
Biochrom (Berlin, Germany). All other chemicals used were of analyt- 
ical grade. 
2.2. Animals 
Correspondence address: K. Decker, Biochemisches Institut der Al- 
bert-Ludwigs-Universitat, Hermann-Herder-Str.7, D-7800 Freiburg 
i.Br.,Germany. Fax: (49) (761) 203-3331. 
Male Wistar rats weighing between 200 and 250 g fed ad libitum 
with Altromin were used throughout. They were from Interfauna 
(Tuttlingen, Germany). 
2.3. Liver perfusion 
Abbreviations: ET-l, endothelin-1; NO, nitric oxide; PG, prosta- 
glandin; sin-l, 3-morpholino-sydnoimine-N-ethylcarbamide; SNP, so- 
Rat livers were perfused in a non-recirculating manner [ 181 using 
dium nitroprusside. 
Krebs-Henseleit buffer containing 118 mM NaCl, 4.74 mM KCl, 1.18 
mM KH,PO,, 1.18 mM MgS04, 24.87 mM NaHCO,, and 2.54 mM 
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CaCl>, pH 7.4, equilibrated with 95% (v/v) Oz and 5% CO,. Perfusion 
pressure was monitored continuously m an open glas capillary tube 
(6 mm) connected to the inflow. A change of 10 cm water corresponds 
to 7.35 mmHg or 980.6 Pascal. 
2.4. Preparation of hepatocytes zn primary culture 
Hepatocytes were prepared under aseptic conditions as described 
previously 1191, plated on collagen-coated ishes (2.5 x IO6 cells, 60 
mm diameter) and kept in primary culture at 37°C. Durmg the flrst 
3 h, cells were incubated with 3 ml RPM1 1640 medium supplemented 
with 10% fetal-calf serum, penicillin 100 U/ml and streptomycin SO 
&ml, thereafter in the same medium containing 5% newborn-calf 
serum. After 24 h, they were kept for 4 h in 25.5 mM glucose and 1 
PM insulin to enhance the synthesis of glycogen. Cells were washed 
free of glucose and stimulated with ET-1 in glucose-free Hank’s me- 
dium, pH 7.4. At the times indicated, glucose concentration in the 
medium was dete~in~ according to Kunst [20]. Protein content in 
primary cultures of hepatocytes was measured according to Bradford 
1211. 
3. RESULTS AND DISCUSSION 
3. I. Endothelin-1 action on the perfused rat liver 
ET-l administered to the isolated perfused rat liver 
induced an increase of the portal vein pressure and 
stimulated glucose output (Fig. 1, A and B). The portal 
pressure started to increase immediately after addition 
of ET-l and reached its maximum (22.4 ? 2.7 cm water) 
between 20 and 25 min (Fig. 1A). After removal of ET-l 
the portal pressure remained at the plateau level for 2 
min and then decreased gradually. The pressure did not 
return to the initial level 30 min after removal of ET-l; 
a small but signi~cantly elevated portal pressure 
(7.5 ? 1.2 cm water) was still present. The kinetics of 
glucose output appeared to differ from the kinetics of 
the change of portal pressure. Within 5 min after addi- 
tion of ET-1 the glucose output was increased 3-fold. 
The glucose output decreased slightly during the follow- 
ing 20 min, rose again at 25 min and decreased gradu- 
ally thereafter (Fig. 1 B). The increase in glucose output 
and portal pressure was dose-dependent (Fig. 1, A and 
B). 0.1 nM ET- 1 induced a maximal increase in portal 
pressure of 6.1 + 1.8 cm water at 30 min and stimulated 
glucose output to 160% of the control value at 10 min. 
10 nM ET-l induced the same maximum of portal pres- 
sure and the biphasic glucose output as 1 nM ET-l. The 
effects of these two concentrations differed from each 
other in their kinetics only. The maximal increase of 
portal pressure appeared already at 12 min after stimu- 
lation with 10 nM ET-l. 
3.2. Effect of extracellular Cci’ on e~dotheIi~-1 action 
ET-l was reported to induce the influx of extracellu- 
lar Ca” into smooth muscle cells [1,6]. To test whether 
extracellular Ca2+ was also required for the increase of 
portal pressure and glycogenolysis, the liver was stimu- 
lated by 1 nM ET-l in the absence of Ca”. Unspecifi- 
cally bound Ca2+ was removed before stimulation with 
ET- I by a 5 min perfusion in Ca’+-free medium contain- 
ing 2 mM EGTA. Under these conditions, ET-l in- 
duced just a small increase of portal pressure (maximal 
level, 2.5 rt 0.8 cm water) (Fig. 1C). The functional in- 
tegrity of the liver after treatment with Ca”-free me- 
dium was checked by stimulating the liver with 1 nM 
ET-l after re-addition of Ca2’. As shown in Fig. lC, the 
liver pretreated with Ca’+-free medium was fully re- 
sponsive to ET- 1 when the perfusion buffer was supple- 
mented with Ca2+; the maximal increase in portal pres- 
sure was 18.61-3.8 cm water. Extracellular Ca2+ was also 
necessary for the increased glucose output induced by 
ET- 1; in the absence of Ca” the ET-l-elicited glucose 
output was suppressed (Fig. lD, diamonds). Addition 
of Ca’+ to the medium restored the increase of glucose 
output. Thus, extracellular Ca2’ is necessary for the 
action of ET-l. 
3.3. Effect of a protein kin~se C inhibitor on endothe~in 
action 
In vascular smooth muscle cells, ET-l has been re- 
ported to activate phospholipase C producing inositol 
phosphates and diacylglycerol[4,5]. Diacylglycerol acti- 
vates protein kinase C leading to the phosphorylation 
of several proteins including filamentous proteins of the 
cytoskeleton and glycogen phosphorylase kinase [22]. 
Recent reports suggest that the protein kinase C-de- 
pendent phosphorylation of filamentous proteins is re- 
sponsible for the long-lasting contraction of vessels that 
is characteristic for ET-l action [8,23]. In stellate cells 
ET-l strongly activates phospholipase C (Kawada et 
al., submitted). To test whether protein kinase C is in- 
volved in the increase of portal pressure and glucose 
Fig. 1. Increase of portal pressure and glucose output after stimulation with ET- 1 m the presence of different effecters. The livers were preperfused 
for 30 min before addition of ET-l. After the indicated times of exposure to ET-l, perfusions were continued for 30 min without any effector. Portal 
pressure and glucose output were determined as described in Materials and Methods. The change of portal pressure was determined m A. C. E, 
G and I. Glucose output was determined in B, D, F, H and J. The rate of glucose output by the untreated perfused liver was constant with a 
coefficient of variation of 11.5% during the experimental period. The closed circles refer to stimulation with 1 nM ET-l. Bars represent he S.D. 
(n = 3). (A and B) Livers were perfused with 10 nM ET-I (closed triangles). or 0.1 nM ET-1 (open diamonds) for 30 min. (C and D) The livers 
were stimulated either with ET- I for 30 min in Ca”-free medium and thereafter in buffer containing Ca’+ (open diamonds), or for 15 min in Ca”-free 
medium, then stimu~ted a second ttme with 1 nM ET-1 in the presence of Ca” (closed dtamonds). To remove uns~clfically bound Ca”, hvers 
were perfused for 5 min with 2 mM EGTA before stimulation in Ca”-free medium. (E and F) Livers were stimulated with 1 nM ET-1 and 20 nM 
staurosporin (closed diamonds). (G and H) Stimulation was performed for 30 min in the presence of 1 nM ET-l and SOpM indomethacin (closed 
triangles) or for 15 min m the presence of 1 nM ET-l and 1 PM Iloprost (open diamonds). (I and J) Livers were perfused with 1nM ET-l and 
100 PM sin-1 (closed triangles). 
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output, stimulation of the perfused liver with ET-l was crease of portal pressure and glucose output was almost 
carried out in the presence of 20 nM staurosporin, an totally inhibited in the presence of staurosporin. These 
inhibitor of protein kinase C (Fig. 1E and F). The in- results indicated that both extracellular Ca2’ and pro- 
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tein kinase C activity were required for the reactions 
induced by ET-l in the perfused liver. 
3.4. Endothelin-1 and eicosanoids 
Stimulated non-parenchymal liver cells are able to 
produce eicosanoids (for a review, see [24]) that induce 
vasocontraction and glycogenolysis in the perfused 
liver, e.g. thromb’oxane A, [25]. Since ET-3, an isoform of 
ET- 1, has been reported recently to induce PGE, pro- 
duction in Kupffer cells [14]. one can assume that the 
effect of ET-l is mediated by eicosanoids. For this rea- 
son, the effects of ET-l were examined in the presence 
of 50 ,uM indomethacin, an inhibitor of cyclooxygenase 
(Fig. 1G and H). However, neither the increase in portal 
pressure nor the stimulation of glycogenolysis induced 
by ET-l were affected by indomethacin. On the con- 
trary, the ET-l-mediated elevation of portal pressure 
was consistently, though not in a highly significant man- 
ner, enhanced in the presence of indomethacin suggest- 
ing that some endogenous eicosanoids might reduce the 
contraction induced by ET-l. As Iloprost, a PGI, ana- 
logue, led to relaxation of precontracted stellate cells in 
culture [26], we tested whether it counteracted the eleva- 
tion of portal pressure caused by ET-l (Fig. 1G). One 
,uM Iloprost suppressed the maximal increase of portal 
pressure induced by ET-l from 22.4 ? 2.7 to 6.8 f 1.4 
cm water. Similarly the stimulation of glucose output 
was strongly reduced in the presence of Iloprost (Fig. 
1H). Therefore, we assume that endogenous PGI, an- 
tagonizes the effect of ET-I in the liver. However, fur- 
ther experiments may be required to show whether ET-l 
stimulates the formation of endogenous PGI, in the 
perfused liver. 
3.5. Endothelin-1 and nitric oxide 
Nitric oxide (NO) is a novel vasodilatory factor pro- 
duced by endothelial cells [27,28], platelets, activated 
macrophages and neutrophiles (for a review, see [29]). 
When NO is released from endothelial cells, it easily 
diffuses into smooth muscle cells underlying endothelial 
cells and leads to cell relaxation by increasing cGMP via 
the activation of soluble guanylate cyclase [30]. In the 
liver, hepatocytes from rats pretreated with Coryne- 
bacterium parvum were shown to produce nitrite and 
nitrate, the oxidation products of NO [31]. Stimulated 
Kupffer cells also synthesized NO [32,33]. On the other 
hand, SNP and sin-l, two substances which liberate 
NO, can react with precontracted stellate cells to induce 
relaxation (Kawada et al., submitted). For this reason, 
we examined whether NO can affect the increase of 
portal pressure and glycogenolysis induced by ET-l. 
100 ,uM sin-l markedly reduced the maximal increase 
of portal pressure caused by ET-l from 22.4 & 2.7 to 
7.8 + 0.5 cm water (Fig. 11). The increased glucose out- 
put by ET-l was only slightly reduced at an initial stage, 
but afterwards it gradually decreased to the basal level 
(Fig. 1 J). The results indicate that contraction induced 
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by ET-l in the perfused liver can be inhibited by the 
action of a NO donor. It is not known whether ET-I can 
induce the production of NO to counterbalance the con- 
traction elicited in this system. 
3.6. Endothelin-I and bile flow 
ET-l also affected bile flow during stimulation with 
ET-l (Table I). The extent of bile flow seems to be 
correlated with portal pressure. In the presence of vaso- 
dilatory agents like sin-l and Iloprost, the biliary flow 
rate was restored to normal values. One can assume that 
in vivo ET-l not only leads to vasocontraction but also, 
perhaps as a secondary phenomenon, to glycogenolysis 
and a reduced bile flow. 
3.7. Effect of endothelin-1 on hepatocytes in primary cul- 
ture 
One or 10 nM ET-l stimulated the rate of glucose 
output of hepatocytes only to a small extent (Fig. 2A); 
at 5 min to 123% and 125%, and at 30 min to 117% and 
114% of the control value, respectively. Even with 
higher concentration (50 nM), the degree of stimulation 
was the same as that for 1 or 10 nM ET-l. These values 
were much lower than those elicited by 2 ,uM glucagon 
(320% of control, Fig. 2B). Obviously, the strong in- 
crease of glucose output by the liver is mediated only in 
part by a direct effect of ET-l on hepatocytes; the first 
glucose peak that appeared 5 min after ET-l addition 
mirrors ET-l action. At that time, the increase of the 
portal pressure was 25% (5.5 * 1.2 cm H,O, n = 3) of 
the maximum. Furthermore, the maximal increase of 
glycogen phosphorylase activity has been found 5 min 
after ET-l [lo]. The second peak of glucose output 
starting 25 min after ET-l addition seems to be due to 
other mechanisms that are related to the change of por- 
tal pressure, e.g. hypoxia in some sinuoids. 
3.8. Concluding remarks 
ET- 1 is a very potent agonist for vasoconstriction and 
glycogenolysis in the liver acting at nanomolar concen- 
trations. The strong increase in portal pressure caused 
by ET-l in the perfused liver could be due to the con- 
Table I 
Influence of vasocontraction on bile flow 
Effecters Bile flow 
@Urnin) 
Increase of portal pressure 
(cm water) 
None 9.8 k 1.0 (n = 11) f0 (n=16) 
1 nM ET-l 5.6 + 1.4 (n = 3) 22.4 + 2.7 (n = 3) 
1 nM ET-l + 8.0; 9.0 6.8*1.4(n=3) 
1 ,uM Iloprost 
1 nM ET-l + 9.7; 11.3 7.8 f 0.5 (n = 3) 
100 PM Sm-I 
The livers were perfused under the conditions described m the legend 
of Fig 1 The values represent means f S.D.; m two instances (n = 2) 
bile flow data are given individually. 
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Fig. 2. Effect of ET-l and glucagon on glycogenolysis n hepatocytes 
in primary cultures. Culture conditions were described in Materials 
and Methods. (A) Time course of glyco~nolysis with different ET-1 
concentrations. Closed diamond, 10 nM ET-l; closed triangle, 1 nM 
ET-l. 100% referred to the glucose output in non-stimulated cells. 
Basal cumulative glucose output was 11 + 1, 16 + 6, 24 ? 9 and 
43 + 14 nmol/mg protein at 0, 5, 15, and 30 mitt, respectively. Mean 
values from 3 independent cell batches 2 SD. are given. Note that the 
rate of glucose output was almost constant during the experimental 
period. (B) Comparison of glycogenolysis induced by ET-l and glu- 
cagon. Glucose was measured after 30 min incubation with effecters. 
traction of stellate cells that envelope the liver sinusoids. 
However, one can not exclude the possibility that ET-I 
also reacts with smooth muscle cells of hepatic blood 
vessels. Extracellular Ca2’ and protein kinase C were 
required for vasocontraction and glycogenolysis. The 
effects of ET- 1 could be reduced by sin- 1, a NO donor, 
and Iloprost, a PGIz anaiogue. Since both, NO and 
PGI,, can be synthesized in the liver, it is tempting to 
assume that they are formed simultaneously in viva to 
counterbalance the action of ET-I. 
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